Food and beverage compositions infused with lipophilic active agents and methods of use thereof
AssigneePoViva Tea, LLC
InventorsMichelle Reillo, Marian E. Washington
Life of this patent
Estimating the term…
Abstract
Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.
Claims18
A process for making cannabinoid infused tea leaves comprising the steps of:
- (i) contacting tea leaves with an oil comprising a cannabinoid and a bioavailability enhancing agent;
- and
- (ii) dehydrating the tea leaves;
- thereby producing the cannabinoid infused tea leaves;
- wherein the cannabinoid infused tea leaves comprise a therapeutically effective amount of the cannabinoid, and further wherein the bioavailability enhancing agent comprises an edible oil comprising long chain fatty acids, wherein the bioavailability of the cannabinoid in a subject is at least 1.5 times greater than the bioavailability of the cannabinoid in the subject in the absence of the bioavailability enhancing agent.
A process for making a cannabinoid infused beverage product comprising the steps of:
- (i) contacting tea leaves with an oil comprising a cannabinoid and a bioavailability enhancing agent;
- (ii) dehydrating the tea leaves, thereby producing cannabinoid infused tea leaves;
- and
- (iii) steeping the cannabinoid infused tea leaves in a liquid, thereby producing the cannabinoid infused beverage product;
- wherein the cannabinoid infused tea leaves comprise a therapeutically effective amount of the cannabinoid, and further wherein the bioavailability enhancing agent comprises an edible oil comprising long chain fatty acids, wherein the bioavailability of the cannabinoid in a subject is at least 1.5 times greater than the bioavailability of the cannabinoid in the subject in the absence of the bioavailability enhancing agent.
Dependencies are inferred from the claim text.